Combination Therapy with Metformin and Empagliflozin for Type 2 Diabetes

Introduction to Combination Therapy

The American Diabetes Association recommends starting with metformin 1,000 mg twice daily plus empagliflozin 10 mg once daily, with the option to increase empagliflozin to 25 mg once daily if additional glycemic control is needed, for patients with type 2 diabetes and normal renal function (eGFR ≥45 mL/min/1.73 m²) 1, 2

The American College of Cardiology suggests a target dose of metformin at 1,000 mg twice daily (2,000 mg total daily dose) 1
The American College of Cardiology recommends increasing metformin gradually as tolerated to minimize gastrointestinal side effects 1
The maximum dose of metformin is 2,550 mg/day (US) or 3,000 mg/day (EU), though doses above 2,000 mg provide minimal additional benefit with worse tolerability 1

For patients with eGFR ≥45 mL/min/1.73 m², no dose adjustment of metformin is required 3
For patients with eGFR 30-44 mL/min/1.73 m², the maximum dose of metformin should be reduced to 1,000 mg daily 3
For patients with eGFR <30 mL/min/1.73 m², metformin is contraindicated 1, 3
The Kidney International journal recommends monitoring eGFR at least annually, and increasing monitoring to every 3-6 months when eGFR falls below 60 mL/min/1.73 m² 3

The Journal of the American College of Cardiology suggests a starting dose of empagliflozin at 10 mg once daily 2, 4, 5
The maximum dose of empagliflozin is 25 mg once daily 2, 4, 5
Both doses of empagliflozin demonstrate cardiovascular and renal benefits, though the 25 mg dose does not provide substantially greater glucose-lowering efficacy at lower eGFR levels 6

For patients with eGFR ≥45 mL/min/1.73 m², no dose adjustment of empagliflozin is required, and both 10 mg and 25 mg can be used 6, 2, 5
For patients with eGFR <45 mL/min/1.73 m², empagliflozin should not be initiated for glycemic control, as glucose-lowering efficacy is reduced 6, 2, 5
For patients with eGFR 20-44 mL/min/1.73 m², empagliflozin 10 mg daily may be continued if already established for cardiovascular and renal protection, even though glycemic benefit is minimal 6, 3
For patients with eGFR <20 mL/min/1.73 m², initiation of empagliflozin is not recommended, but it may be continued if tolerated until dialysis for cardiovascular/renal benefits 6

The American Diabetes Association recommends withholding metformin during severe illness, vomiting, dehydration, or acute kidney injury to prevent lactic acidosis 1
The American Diabetes Association suggests monitoring vitamin B12 levels periodically and supplementing if deficient, particularly in patients with anemia or neuropathy 1
The Journal of the American College of Cardiology recommends withholding empagliflozin at least 3 days before major surgery or procedures requiring prolonged fasting to prevent postoperative ketoacidosis 2, 7
The American College of Cardiology advises assessing volume status before initiation of empagliflozin and using caution with concurrent diuretics, ACE inhibitors, or ARBs due to risk of volume depletion and orthostatic hypotension 1
The American Diabetes Association recommends educating patients about the rare but serious risk of diabetic ketoacidosis, even with normal glucose levels 1